Our current study intentionally focused on the diagnostic performance of FABP3 methylation especially for early-stage cancer (stage I and II), and thus, in lack of the prognostic information while early-stage TC is often curable upon timely diagnosis and treatment. The gene discussed is FABP3; the disease is cancer.